Future directions may also include identifying the nature of relationship between multi-day BRANCH learning curves and AD biomarkers such as amyloid and tau in participants longitudinally beyond the cognitive unimpaired stage [12]. The gene discussed is MAPT; the disease is Alzheimer disease.